Get the Stockscreener App
32.74
0.27%
-0.09
After Hours:
32.74
Immunocore Holdings Plc Adr Stock (IMCR) Latest News
Does Immunocore (IMCR) Have the Potential to Rally 112.82% as Wall Street Analysts Expect? - MSN
Wall Street Analysts Predict an 112.56% Upside in Immunocore (IMCR): Here's What You Should Know - MSN
New Strong Buy Stocks for November 26th - Yahoo Finance
FATE Presents Encourgaing Data From Lupus Study, Stock Gains - Barchart
Incyte Pauses Enrollment in Chronic Spontaneous Urticaria Study - Nasdaq
ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap - Yahoo Finance
Immunocore (IMCR) Upgraded to Buy: Here's Why - MSN
Immunocore's SWOT analysis: biotech stock faces pivotal moment amid PRAME data - Investing.com India
FATE Q3 Earnings Beat On Higher Revenues, Pipeline In Focus - Barchart
SpringWorks' Q3 Loss Narrower Than Expected, Revenues Miss Mark - Barchart
Mirum's Q3 Earnings Beat Estimates, 2024 Revenue View Raised - Barchart
Mizuho downgrades Immunocore stock to Neutral, slashes PT to $38 from $72 - Investing.com
Rocket Pharmaceuticals' Q3 Earnings Beat, Pipeline In Focus - Barchart
Immunocore repays Pharmakon loan, ends agreement - Investing.com India
PBYI Beats Q3 Earnings & Revenue Estimates, Revises '24 View, Stock Up - Barchart
Immunocore Holdings earnings beat by $0.50, revenue topped estimates - Investing.com India
Immunocore shares maintain buy rating on HIV treatment potential - Investing.com
Immunocore Holdings PLC (IMCR) Q2 2024 Earnings Call Highlights: Strong US Growth and Strategic ... - Yahoo Finance
Immunocore stock hits 52-week low at $29.72 amid market challenges - Investing.com
Immunocore's SWOT analysis: biotech stock poised for growth amid clinical trials - Investing.com UK
Financial Fitness Check: Examining Immunocore Holdings plc ADR (IMCR)’s Key Ratios - The Dwinnex
Immunocore stock hits 52-week low at $32.07 amid market challenges - Investing.com
TD Cowen maintains Buy rating on Immunocore shares on ovarian cancer drug data - Investing.com India
Quarterly Metrics: Quick and Current Ratios for Immunocore Holdings plc ADR (IMCR) - The Dwinnex
Immunocore Holdings plc ADR (IMCR) is looking forward to a strong quarter - SETE News
Immunocore stock hits 52-week low at $32.84 amid market challenges - Investing.com
Ratios Revealed: Decoding Immunocore Holdings plc ADR (IMCR)’s Financial Health - The Dwinnex
Have you been able to find a good deal on Immunocore Holdings plc ADR’s shares? - US Post News
Immunocore Holdings plc (IMCR): Top ADR Stock According to Hedge Funds - Yahoo Finance UK
The growth track for Immunocore Holdings plc ADR (IMCR) has changed recently - SETE News
The Potential Rise in the Price of Sun Communities, Inc. (SUI) following insiders activity - Knox Daily
Insider Sale Alert: Terns Pharmaceuticals Inc [TERN] – Is it Time to sell? - Knox Daily
Immunocore Holdings plc ADR (IMCR) may enjoy gains as insiders got busy in the recent days - Knox Daily
Monitoring Brookline Bancorp, Inc. (BRKL) after recent insider movements - Knox Daily
Immunocore Holdings plc ADR [IMCR] Shares Fall -4.18% on Thursday - Knox Daily
Financial Health Report: Immunocore Holdings plc ADR (IMCR)’s Ratios Tell a Tale - The Dwinnex
Insider Sale: President Brian Hole Sells Shares of Willis Lease Finance Corp (WLFC) - Yahoo Finance UK
IMCR’s 52-Week Rollercoaster: From $33.04 to $76.98 – What’s Next for Investors? - The InvestChronicle
Immunocore CFO to depart, company seeks replacement - Investing.com
IMCR’s price-to-free cash flow ratio: How it affects investment decisions - US Post News
Immunocore Holdings plc ADR [IMCR] Insider Activity: An Update for Investors - Knox Daily
Super Micro slides 8% as date nears for stock split - MSN
Top 10 ADR Stocks To Buy According to Hedge Funds - Insider Monkey
Ratio Examination: Immunocore Holdings plc ADR (IMCR)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Examining the Potential Price Growth of Immunocore Holdings plc ADR (IMCR) - Knox Daily
Cancer Immunotherapy Market Size Expected to Touch USD 530.2 Billion by 2034, With 14.2% CAGR Growth: Prophecy Market Insights - GlobeNewswire Inc.
South Korea Cancer Immunotherapy Market Size & Outlook, 2030 - Grand View Research
Brazil Cancer Immunotherapy Market Size & Outlook, 2030 - Grand View Research
1.61%
1.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):